A Phase 1 interventional study of Garetosmab and Matching Placebo in Obesity, sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity.
The aim of the study is to see how safe and tolerable the study drug is.
The study is looking at several other research questions, including:
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized per the protocol
Drug: Garetosmab
Randomized per the protocol
Drug: Garetosmab
Randomized per the protocol
Drug: Matching Placebo
Administered per the protocol
Also known as: REGN2477
Administered per the protocol
Incidence of treatment-emergent adverse events (TEAEs)
Time frame: Through Week 32
Severity of TEAEs
Time frame: Through Week 32
Change in serum Follicle Stimulating Hormone (FSH) level in response to gonadotropin-releasing hormone (GnRH) injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Percent change in serum FSH level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Change in serum Luteinizing Hormone (LH) level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Percent change in serum LH level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Change in serum total testosterone level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Percent change in serum total testosterone level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Change in serum free testosterone level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Percent change in serum free testosterone level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Change in serum estradiol level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Percent change in serum estradiol level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Change in serum 17-hydroxyprogesterone (17-OHP) level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Percent change in serum 17-OHP level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Change in serum Dehydroepiandrosterone Sulphate (DHEA-S) level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Percent change in serum DHEA-S level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Change in serum androstenedione level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Percent change in serum androstenedione level in response to GnRH injection
Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH
Change in cortisol level in response to Adrenocorticotropic Hormone (ACTH) level injection
Time frame: Pre-ACTH Baseline, Through Week 20 post-ACTH
Percent change in cortisol level in response to ACTH injection
Time frame: Pre-ACTH Baseline, Through Week 20 post-ACTH
Concentrations of garetosmab in serum
Time frame: Through Week 32
Concentrations of total activin A in serum
Time frame: Through Week 32
Change in bleeding time
Time frame: Baseline, At Week 8
Percent change in bleeding time
Time frame: Baseline, At Week 8
Change in thrombin time
Time frame: Baseline, At Week 8
Percent change in thrombin time
Time frame: Baseline, At Week 8
Change in Activated Partial Thromboplastin Time (aPTT)
Time frame: Baseline, At Week 8
Percent change in aPTT
Time frame: Baseline, At Week 8
Change in Prothrombin Time (PT)
Time frame: Baseline, At Week 8
Percent change in PT
Time frame: Baseline, At Week 8
Change in International Normalized Ratio (INR)
Time frame: Baseline, At Week 8
Percent change in INR
Time frame: Baseline, At Week 8
Change in platelets count
Time frame: Baseline, At Week 8
Percent change in platelets count
Time frame: Baseline, At Week 8
Change in serum ACTH level
Time frame: Baseline, Through Week 20
Percent change in serum ACTH level
Time frame: Baseline, Through Week 20
Change in serum FSH level
Time frame: Baseline, Through Week 20
Percent change in serum FSH level
Time frame: Baseline, Through Week 20
Change in serum LH level
Time frame: Baseline, Through Week 20
Percent change in serum LH level
Time frame: Baseline, Through Week 20
Change in serum Thyroid Stimulating Hormone (TSH) level
Time frame: Baseline, Through Week 20
Percent change in serum TSH level
Time frame: Baseline, Through Week 20
Change in serum Thyroxine (T4) level
Time frame: Baseline, Through Week 20
Percent change in serum T4 level
Time frame: Baseline, Through Week 20
Change in serum total testosterone level
Time frame: Baseline, Through Week 20
Percent change in serum total testosterone level
Time frame: Baseline, Through Week 20
Change in serum free testosterone level
Time frame: Baseline, Through Week 20
Percent change in serum free testosterone level
Time frame: Baseline, Through Week 20
Change in serum 17-OHP level
Time frame: Baseline, Through Week 20
Percent change in serum 17-OHP level
Time frame: Baseline, Through Week 20
Change in serum estradiol level
Time frame: Baseline, Through Week 20
Percent change in serum estradiol level
Time frame: Baseline, Through Week 20
Change in serum DHEA-S level
Time frame: Baseline, Through Week 20
Percent change in serum DHEA-S level
Time frame: Baseline, Through Week 20
Change in serum androstenedione level
Time frame: Baseline, Through Week 20
Percent change in serum androstenedione level
Time frame: Baseline, Through Week 20
Change in serum Human Growth Hormone (HGH) level
Time frame: Baseline, Through Week 20
Percent change in serum HGH level
Time frame: Baseline, Through Week 20
Change in serum Insulin-like Growth Factor (IGF)-1 level
Time frame: Baseline, Through Week 20
Percent change in serum IGF-1 level
Time frame: Baseline, Through Week 20
Change in serum cortisol level
Time frame: Baseline, Through Week 20
Percent change in serum cortisol level
Time frame: Baseline, Through Week 20
Incidence of Anti-Drug Antibodies (ADA) to garetosmab
Time frame: Through Week 32
Titer of ADA to garetosmab
Time frame: Through Week 32
No study locations are listed for this record.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for May 2025; primary completion for Jun 2026, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garetosmab